2020 Guide to Patient Support Services

Sun Pharma

Sun Pharma offers comprehensive patient support services to help patients access its oncology medications, including Yonsa (abiraterone acetate), Odomzo (sonidegib), and imatinib mesylate.

Yonsa is indicated for the treatment of metastatic castration-resistant prostate cancer, in combination with methylprednisolone. Odomzo is indicated for the treatment of adults with relapsed, locally advanced basal-cell carcinoma, after surgery or radiation therapy, if applicable. Imatinib mesylate is indicated for the treatment of several types of blood cancer (Table).

Sun Pharma offers individual patient support programs for each of its oncology medications.

SUN PHARMA PATIENT ASSISTANCE PROGRAMS

Yonsa Support

Yonsa Support offers comprehensive patient support services for patients who are prescribed Yonsa. The Yonsa Support Co-pay Program provides copay assistance for patients who have commercial insurance. Eligible patients may pay as little as $10 for Yonsa, for a maximum benefit of $5000 per prescription and up to a $12,000 benefit annually.

Yonsa Support Early Access Program provides free Yonsa for up to 30 days to eligible patients who are facing a delay in medication coverage or those facing an initial denial of prior authorization.

Through Yonsa Support, eligible patients who do not have commercial insurance will receive help with the cost of Yonsa through the Sun Pharma Patient Assistance Program.

Odomzo Patient Access Program

Patients with commercial or private insurance may be eligible for the Odomzo Co-pay Assistance Program. Eligible patients may pay as little as $10 per month for their prescription of Odomzo, with a maximum annual benefit of $15,000.

The Odomzo Patient Access Program provides reimbursement assistance to providers, including help with benefit authorization ­requirements and appeals and denials. The program works with specialty pharmacies to fulfill prescriptions and provides financial support for eligible patients who are prescribed Odomzo.

Imatinib Savings Card Program

Patients who are prescribed imatinib mesylate may be eligible for the Imatinib Savings Card. Through this program eligible patients may receive up to a 30-day supply of imatinib at no charge, provided that the out-of-pocket cost for the medication is less than $50.

Sun Pharma Patient Assistance Program

Sun Pharma has partnered with Rx Outreach to launch the Sun Pharma Patient Assistance Program. This program allows eligible patients with a low income to gain access to their prescribed Sun Pharma oncology medications at reduced cost.

ELIGIBILITY

Sun Pharma Co-Pay Assistance Programs

To be eligible for any of the Sun Pharma copay assistance programs offered to those who have been prescribed Yonsa, Odomzo, or imatinib, patients must:

  • Be a resident of the United States or its territories
  • Have commercial or private insurance that covers the prescribed medication, including Yonsa, Odomzo, or imatinib mesylate
  • Have a valid prescription for either Yonsa, Odomzo, or imatinib mesylate
  • Have no insurance coverage through Medicare, Medicaid, or any other federal or state program, pay cash for their prescription, or not have any plan that is reimbursing the entire cost of their prescribed drug.

Patients who are prescribed Odomzo must be aged ≥18 years to qualify for the copay program for Odomzo.

Sun Pharma Patient Assistance Program

Click here for information about the Sun Pharma Patient Assistance Program and its eligibility requirements, call 844-502-5950.

APPLICATION & ENROLLMENT

Yonsa Support

Patients may be enrolled in Yonsa Support to have access to Yonsa, by completing and submitting the Yonsa Support enrollment form. The completed enrollment form must be faxed to 877-872-6575 or mailed to the address on the enrollment form, along with copies of both sides of the patient’s insurance card. Call 855-449-6672 for any questions about the enrollment process.

Odomzo Patient Access Program

Patients may be enrolled in the Odomzo Patient Access Program by completing and submitting the Odomzo Patient Access Program enrollment form. The completed enrollment form must be faxed to 877-872-6575 or mailed to the address on the enrollment form, along with copies of both sides of the patient’s insurance card. Please call 844-563-6696 for assistance with the enrollment process.

Sun Pharma Patient Assistance Program

Click here for information about the enrollment process in the Sun Pharma Patient Assistance Program, call 844-502-5950.

TABLE SUN PHARMA ONCOLOGY DRUGS

Drugs
Indications
Patient support programs

Drug
Imatinib mesylate
Indications
Patient support programs

Drug
Odomzo (sonidegib)
Indications
Treatment of adults with locally advanced basal-cell carcinoma that relapsed after surgery or radiation or cannot be removed by surgery or radiation
Patient support programs

Drug
Yonsa (abiraterone acetate)
Indications
Treatment of metastatic castration-resistant prostate cancer, in combination with methylprednisolone
Patient support programs

PDGFR indicates platelet-derived growth factor receptor; Ph+, Philadelphia chromosome positive.

Imatinib mesylate Indications

First-line treatment of Ph+ chronic myeloid leukemia in chronic phase; treatment of blast crisis, accelerated-, or chronic-phase Ph+ chronic myeloid leukemia after failure of interferon-alpha therapy; adults with relapsed/refractory Ph+ acute lymphoblastic leukemia; adults with myelodysplastic/myeloproliferative diseases associated with PDGFR gene rearrangements; adults with aggressive systemic mastocytosis without the D816V c-kit mutation or with c-kit mutational status unknown; adults with hyper-eosinophilic syndrome or chronic eosinophilic leukemia with FIP1L1-PDGFRα fusion kinase, or those whose FIP1L1-PDGFRα ­fusion kinase status is negative or unknown; adults with unresectable, recurrent, or metastatic dermatofibrosarcoma protuberans

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: